Sylvant (Siltuximab: Recordati Rare Diseases) Market Research Report 2026: Increasing Adoption Of Targeted Il-6 Inhibitor Therapies And Growing Use In Rare Immunological Disorders - Forecast To 2035

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities include increased diagnosis of multicentric Castleman disease, precision immunotherapy, and expansion of specialty clinics. Growth is driven by targeted IL-6 therapies, rising global access to rare disease treatments, and regional biologics manufacturing expansion. Asia-Pacific leads future growth.

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Sylvant (Siltuximab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Sylvant market report provides detailed insights, including market size, competitor analysis, and trend forecasts, equipping stakeholders with strategic data to navigate the industry landscape effectively. This comprehensive resource offers an in-depth perspective on both current and future industry scenarios.

The Sylvant (siltuximab) market has experienced notable growth, driven by increased diagnosis of multicentric Castleman disease (MCD), improved awareness of cytokine-driven disorders, and advances in monoclonal antibody development. The clinical use of targeted biologics has expanded, contributing to the market's evolution. Research into additional inflammatory indications and greater demand for precision immunotherapy solutions are expected to continue fueling growth.

During the forecast period, the market is likely to benefit from advancements in biologic drug formulation, an expanding network of specialty clinics, and enhanced access to rare disease treatments globally. Notable trends include the adoption of targeted IL-6 inhibitor therapies and their increased use in rare immunological disorders. The focus on inflammatory pathway modulation and patient outcome monitoring is also shaping the future landscape.

The rising prevalence of MCD is a significant driver for Sylvant. The drug operates by inhibiting interleukin-6 (IL-6), controlling abnormal lymph node growth and reducing inflammation as part of treatment. Highlighting this need, Consult QD noted in 2025 that FDA-approved Sylvant was used by just 22% of U.S. iMCD patients, indicating a substantial unmet demand.

Precision medicine's emphasis on individualized patient care is further propelling the Sylvant market. This approach leverages patient-specific genetic and environmental data, making therapies like Sylvant, with its IL-6 targeting strategy, more effective. In 2024, the FDA saw accelerated approvals for personalized treatments, an indication of this trend's rising traction.

Companies in the Sylvant market are focusing on monoclonal antibody therapies to address the need for precise treatments. These antibodies target disease-specific proteins, thus optimizing immune response and patient outcomes. In 2024, the European Commission approved Sylvant for treating MCD, marking a significant regulatory milestone and reinforcing its therapeutic value.

North America dominated the market in 2025, supported by robust infrastructure and a higher prevalence of MCD. However, Asia-Pacific is projected to grow rapidly, driven by expanding healthcare initiatives and investments in biotech solutions. The report covers regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, and others, offering a comprehensive analysis of international developments.

Report Scope

• Indication: Multicentric Castleman Disease, HIV-Associated Multicentric Castleman Disease, Non-Hodgkin Lymphoma
• Application: Injections, Vials, Lyophilized Powder, Solution For Infusion, Prefilled Syringes
• End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care

Major Trends

• Increasing Adoption of Targeted Il-6 Inhibitor Therapies
• Growing Use in Rare Immunological Disorders
• Expansion of Monoclonal Antibody Treatment Protocols
• Enhanced Focus on Inflammatory Pathway Modulation
• Improved Patient Outcome Monitoring

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11052026004107003653ID1111097722